Comparative Pharmacology
Head-to-head clinical analysis: ULTRAM versus ZOHYDRO ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAM versus ZOHYDRO ER.
ULTRAM vs ZOHYDRO ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Zohydro ER is a pure opioid agonist with relative selectivity for mu-opioid receptors, although it can interact with other opioid receptors at higher doses. Its primary therapeutic action is analgesia via binding to mu-opioid receptors in the central nervous system, leading to activation of descending inhibitory pathways and modulation of pain perception.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day (for extended-release: 100 mg once daily, titrated up to 300 mg once daily).
Initial: 20 mg orally every 24 hours; titrate in increments of 10-20 mg every 3-7 days as needed; maximum dose 200 mg every 24 hours.
None Documented
None Documented
Tramadol: ~6 hours; M1 metabolite (O-desmethyltramadol): ~7 hours; prolonged in renal/hepatic impairment
Terminal elimination half-life is approximately 10.6 hours (range 8-17 hours) due to extended-release formulation; immediate-release hydromorphone half-life is 2-3 hours. Clinically, steady-state is achieved after 3-5 days of dosing.
Renal: ~90% (tramadol and metabolites; conjugated metabolites are major), Fecal: ~10%
Primarily renal excretion of hydromorphone-3-glucuronide (H3G, ~60%), unchanged hydromorphone (~15%), and other conjugates. Fecal excretion accounts for ~25%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic